Analytical Similarity Assessment in Biosimilar Product Development
Auteur : Chow Shein-Chung
This book focuses on analytical similarity assessment in biosimilar product development following the FDA?s recommended stepwise approach for obtaining totality-of-the-evidence for approval of biosimilar products. It covers concepts such as the tiered approach for assessment of similarity of critical quality attributes in the manufacturing process of biosimilar products, models/methods like the statistical model for classification of critical quality attributes, equivalence tests for critical quality attributes in Tier 1 and the corresponding sample size requirements, current issues, and recent developments in analytical similarity assessment.
Author
Shein-Chung Chow, Ph.D, is currently an Associate Director at Office of
Biostatistics, Center for Drug Evaluation and Research, United States Food
and Drug Administration (FDA). Prior to joining FDA, Dr. Chow was a
Professor at Duke University School of Medicine, Durham, NC. He was
also a special government employee (SGE) appointed by the FDA as an
Advisory Committee member and statistical advisor to the FDA. Prior to
that, Dr. Chow also held various positions in the pharmaceutical industry
such as Vice President at Millennium, Cambridge, MA, Executive Director at
Covance, Princeton, NJ, and Director and Department Head at Bristol-Myers
Squibb, Plainsboro, NJ. Dr. Chow is the Editor-in-Chief of the Journal of
Biopharmaceutical Statistics and the Editor-in-Chief of the Biostatistics Book Series
at Chapman and Hall/CRC Press, Taylor & Francis Group. He was elected
Fellow of the American Statistical Association and an elected member of the
ISI (International Statistical Institute). Dr. Chow is the author or co-author of
over 300 methodology papers and 29 books including Designs and Analysis
of Bioavailability and Bioequivalence Studies, Sample Size Calculations in Clinical
Research, Adaptive Design Methods in Clinical Trials, Translational Medicine,
Design and Analysis of Clinical Trials, and Quantitative Methods for Traditional
Chinese Medicine Development.
Date de parution : 12-2020
15.6x23.4 cm
Date de parution : 08-2018
15.6x23.4 cm
Thèmes d’Analytical Similarity Assessment in Biosimilar Product... :
Mots-clés :
Analytical Similarity Assessment; Biosimilar Product; biosimilarity; Biosimilar Product Development; FDA; Reference Product; bioequivalence; BPCI Act; drug development; Reference Lots; clinical trials; Fundamental Bioequivalence Assumption; sample size; FDA Draft Guidance; Biosimilarity Assessment; Test Lots; Equivalence Test; SUR Model; FDA’s Current Thinking; PD Similarity; NMS; Non-inferiority Margin; Vitro Bioequivalence; Ich Q8; Generic Drug Products; Ich Q2R1; Ich Q5C; Similar Biological Medicinal Product; Sample Size Calculation; Simultaneous Confidence Interval; Innovator Biological Product